1Can anti-osteoporosis drugs be selected based on bone turnover markers?ZHANG Zhen-linSYMPOSIUM·CLINICAL DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS629-6322Definition of treatment to target and selection of therapeutic regimens for osteoporosisYUE HuaSYMPOSIUM·CLINICAL DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS633-6363Attention to sequential treatment for osteoporosisWANG Jia-jia, WANG OuSYMPOSIUM·CLINICAL DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS637-6414Post-target management of anti-resorptive agents based on mechanistic differences:bisphosphonate drug holidays versus denosumab sequential therapyWANG Qin, CHEN De-caiSYMPOSIUM·CLINICAL DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS642-6475Reasonable application of anabolic bone agentsLIN Ying, HOU Jian-mingSYMPOSIUM·CLINICAL DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS648-6516Rational use of vitamin D in the treatment of osteoporosisXU Feng, XIE Zhong-jianSYMPOSIUM·CLINICAL DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS652-6557Management of obesity-related metabolic comorbidities in adults:a consensus statement and endocrinologist expert recommendationsEndocrinology and Metabolism Professional Committee,National Association of Health Industry and Enterprise Management, MU Yi-ming, YU Xue-feng, ZHU Da-longEXPERT RECOMMENDATION656-6708Association between left ventricular remodeling and diastolic dysfunction with bone mineral density in elderly patients with T2DMLIU Yu-rong, JIANG Jian-xiang, DU Pei-yan, ZHANG Tong-qian, LYU Hai-hongORIGINAL CONTRIBUTION671-6779Predictive value of cardiometabolic index combined with triglyceride glucose index in long-term prognosis of patients with acute myocardial infarctionWANG Kai-yang, YONG Jia-hui, TAO Jing, SHEN Xin, YANG Yi-ningORIGINAL CONTRIBUTION678-685